IFNG and neoplasm: HER2-specific CAR-T cells have also been investigated, and in xenograft mouse GBM model, this led to tumour regression and a HER2-dependent anti-tumour response with increased production of IFN-γ and IL-2.137 A phase 1 trial is currently ongoing which will test the safety and efficacy of using HER2-specific CARs in patients with recurrent GBM (NCT02442297).